Sanofi SA

SAN

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Sanofi SA News & Analysis

retirement

The top shares of Australia’s best performing super funds

And our equity analysts’ outlook for the stocks.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,875.3060.000.68%
CAC 407,766.2141.96-0.54%
DAX 4024,060.29100.35-0.42%
Dow JONES (US)44,023.29436.36-0.98%
FTSE 1008,938.3259.74-0.66%
HKSE24,590.12386.801.60%
NASDAQ20,677.8037.470.18%
Nikkei 22539,678.02218.400.55%
NZX 50 Index12,689.6310.940.09%
S&P 5006,243.7624.80-0.40%
S&P/ASX 2008,630.3059.900.70%
SSE Composite Index3,505.0014.65-0.42%

Market Movers